Icagen Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Icagen Inc (ICGND) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Icagen Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 14M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+2.2% annualized vs trailing 12 months).
- Peer revenue share: Icagen Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ICGND Sales vs. its Competitors, Q3 2019
Icagen Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Laboratories industry grew revenue 5.7% year over year, combined, vs 19.7% for Icagen Inc. Icagen Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Icagen Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Icagen, Inc. | No | No | No | Yes |
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) | 37.50 % (3 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.